Related Experiment Video
Updated: Sep 29, 2026
Development and Standardization of an Ex Vivo Micromethod for Intracellular Quantification of Vincristine in Primary ALL Cells by LC-MS/MS
Published on: January 23, 2026
Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine
Camille Haisley-Royster1, Odile Enjolras, Ilona J Frieden
1Duke University Medical Center, Durham, NC, USA.
Purpose:
Kasabach-Merritt phenomenon (KMP) is characterized by profound thrombocytopenia, microangiopathic hemolytic anemia, a consumptive coagulopathy, and an enlarging vascular lesion. The syndrome develops in infancy and is associated with a high morbidity and mortality rate. The purpose of this study was to assess the effectiveness of vincristine in the treatment of KMP.
Methods:
We retrospectively reviewed the clinical and laboratory data of 15 patients with KMP treated with vincristine at 9 institutions across the United States, South America, and Europe.
Results:
All 15 patients had profound thrombocytopenia and consumption of fibrinogen at presentation. Ten patients had biopsies of their lesions, and results included five (33.3%) kaposiform hemangioendotheliomas, three (20%) tufted angiomas, one lesion (6.7%) with features of both kaposiform hemangioendothelioma and tufted angioma, and one (6.7%) unclassified vascular tumor. All 15 patients had an increase in platelet count of at least 20,000 with an average response time of 4.0 weeks after initiation of vincristine therapy. Thirteen patients had an increase in fibrinogen level of 50 mg/dL with an average response time of 3.4 weeks. In 13 patients there was a significant decrease in the size of the vascular lesion. The average duration of treatment was 21.5 (+/-12.6) weeks. Four patients (26%) relapsed. All four were successfully treated with a second course of vincristine. Complications included one patient with abdominal pain, one patient with transient loss of deep tendon reflexes, and one patient with irritability.
Conclusion:
Vincristine presents a safe and sometimes effective treatment option in the management of KMP.
Insights
Vincristine effectively treats Kasabach-Merritt phenomenon (KMP), improving platelet counts, fibrinogen levels, and reducing lesion size. While generally safe, some patients experienced relapses, successfully managed with repeat vincristine courses.
Area of Science:
- Pediatric Hematology
- Vascular Anomalies
- Oncology
Background:
- Kasabach-Merritt phenomenon (KMP) is a rare, severe condition in infants characterized by thrombocytopenia, hemolytic anemia, coagulopathy, and vascular tumors.
- KMP is associated with significant morbidity and mortality, necessitating effective treatment strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of vincristine in treating Kasabach-Merritt phenomenon (KMP).
Main Methods:
- Retrospective review of clinical and laboratory data from 15 KMP patients treated with vincristine across multiple international institutions.
- Analysis of treatment response, including platelet counts, fibrinogen levels, vascular lesion size, and adverse events.
Main Results:
- All patients showed improvement in thrombocytopenia and consumptive coagulopathy with vincristine therapy.
- Significant increases in platelet counts (average 4.0 weeks) and fibrinogen levels (average 3.4 weeks) were observed.
- Vascular lesion size decreased in 13 patients; 26% relapsed but responded to a second vincristine course. Complications were mild and transient.
Conclusions:
- Vincristine is a safe and effective treatment option for Kasabach-Merritt phenomenon (KMP).
- It demonstrates significant efficacy in managing the hematologic abnormalities and vascular lesions associated with KMP.
Related Concept Videos
02:56Treatment Resistant Cancers
01:10Drugs that Destabilize Microtubules
02:56Treatment Resistent Cancers